Trial · NCT02464228
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Cohort AITL | 56.3 | 95% Confidence Interval 39.3 to 71.8 | percentage of participants | |
| Objective Response Rate (ORR) | Cohort PTCL-NOS | 7.1 | 95% Confidence Interval 0.2 to 33.9 | percentage of participants | |
| Objective Response Rate (ORR) | Cohort PTCL-NOS, CXCL12+ | 40.0 | 95% Confidence Interval 12.2 to 73.8 | percentage of participants | |
| Objective Response Rate (ORR) | Cohort Other | 0.0 | 95% Confidence Interval 0.0 to 84.2 | percentage of participants | |
| Progression-free Survival (PFS) | Cohort AITL | 3.6 | 95% Confidence Interval 1.9 to 8.3 | months | |
| Progression-free Survival (PFS) | Cohort PTCL-NOS | 2.1 | 95% Confidence Interval 1.4 to 4.0 | months | |
| Progression-free Survival (PFS) | Cohort PTCL-NOS, CXCL12+ | 5.3 | 95% Confidence Interval 1.8 to 11.1 | months | |
| Progression-free Survival (PFS) | Cohort Other | 1.4 | 95% Confidence Interval 1.1 to 1.6 | months | |
| Duration of Response (DOR) | Cohort AITL | 7.8 | 95% Confidence Interval 2.0 to 16.3 | months | |
| Duration of Response (DOR) | Cohort PTCL-NOS | 1.0 | 95% Confidence Interval NA to NA | months | |
| Duration of Response (DOR) | Cohort PTCL-NOS, CXCL12+ | 2.8 | 95% Confidence Interval 2.0 to NA | months | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort AITL | TEAEs | 38 | Participants | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort PTCL-NOS | TEAEs | 14 | Participants | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort PTCL-NOS, CXCL12+ | TEAEs | 11 | Participants | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort Other | TEAEs | 2 | Participants | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort AITL | Serious TEAEs | 21 | Participants | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort PTCL-NOS | Serious TEAEs | 8 | Participants | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort PTCL-NOS, CXCL12+ | Serious TEAEs | 8 | Participants | |
| Number of Subjects That Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Cohort Other | Serious TEAEs | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02464228/results